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Abstract
Ca2+ increases in the heart control both contraction and transcription. To accommodate a short-term
increased cardiovascular demand, neurohormonal modulators acting on the cardiac pacemaker and
individual myocytes induce an increase in frequency and magnitude of myocyte contraction respectively.
Prolonged, enhanced function results in hypertrophic growth of the heart, which is initially also associated
with greater Ca2+ signals and cardiac contraction. As a result of disease, however, hypertrophy progresses
to a decompensated state and Ca2+ signalling capacity and cardiac output are reduced. Here, the role that
Ca2+ plays in the induction of hypertrophy as well as the impact that cardiac hypertrophy and failure has
on Ca2+ fluxes will be discussed.
Introduction
The co-ordinated and efficient contraction of the four
chambers of the heart is essential to ensure blood supply to
the body.Moreover, it is equally critical for the heart to be able
to modify its output to accommodate the changing needs of
the organism from states of rest to activity. It is therefore not
surprising that any factors that contribute to a loss of rhythm
or contractility give rise to pathological consequences.
Indeed, heart disease is a significant cause of mortality, being
responsible, in 2004, for 137700 deaths in the U.K., equating
to 24% of all deaths [1]. These statistics surpass the 33000
deaths a year from lung cancer, 16000 deaths from colorectal
cancer and 13000 deaths from breast cancer. Decompensated
cardiac hypertrophy is the most important risk factor for
heart failure in humans [2]. Cardiac hypertrophy is defined
by an increase in the muscle mass of the heart due to
cellular enlargement without any proliferation (Figure 1) [3].
Under physiological conditions that involve a requirement
for increased cardiac output, such as those experienced by
performance athletes and during pregnancy, hypertrophy is
an adaptive response (also known as compensated hyper-
trophy) [3,4]. Under pathological conditions, such as hy-
pertension, viral infection or due to mutations in genes
encoding sarcomeric proteins, hypertrophy is a maladaptive
response and progresses to dilated cardiomyopathy with
associated fibrosis, arrhythmias and sudden death (also
known as decompensated hypertrophy) [3,4].
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To understand the molecular mechanisms that control car-
diac hypertrophy and to discover targets for pharmacological
intervention, research has focused on identifying and charac-
terizing the signalling pathways and neurohumoral factors
that contribute to cellular remodelling [4–7]. This research
has uncovered that hypertrophic gene transcription is induced
downstream of a web of multiple interdependent signalling
pathways including those regulated by MAPK (mitogen-
activated protein kinase) [7,8], PI3K (phosphoinositide 3-
kinase) [9,10], PKC (protein kinaseC) [11,12] andCa2+ [6,13–
15] (Figure 2). These pathways are engaged following the
activation of diverse classes of cell-surface receptors present
in cardiac mycoytes, including (i) Gq-coupled receptors such
as that liganded by the vasoactive peptide ET-1 (endothelin-
1) [16,17], (ii) tyrosine kinase-like receptors, such as those
activated by IGF (insulin-like growth factor) [18], and
(iii) Gs-coupled receptors such as the β-adrenergic receptor,
which plays such a profound role in cardiac biology [19,20].
Moreover, mechanical stretch and increased/modified Ca2+
cycling itself also activate the signalling pathways necessary
for hypertrophic remodelling [21,22].
Ca2+ signalling to hypertrophy
As well as being directly responsible for stimulating myocyte
contraction, Ca2+ also plays a key role in regulating the
expression of hypertrophy-associated genes [6,23]. To acutely
respond to greater cardiovascular demand, cardiac output
is enhanced through increased Ca2+ fluxes. Longer-term
requirements for greater cardiac output are brought about
through hypertrophic growth. It is not therefore surprising
that increased Ca2+ cycling would also be considered a
trigger for the induction of hypertrophy; more work, more
Ca2+, more gene transcription, more heart. The reports that
hypertrophy can be induced by simply enhancing Ca2+
fluxes, via electrical ‘pacing’ in both cellular and animal
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Figure 1 ET-1-induced hypertrophy in neonatal rat myocytes
Spontaneously beating primary cultures of rat neonatal cardiac myocytes
exhibit hypertrophic growth following treatment with ET-1 (100 nM)
for 24 h. ET-1-treated myocytes have a greater surface area and
sarcomeric organization as revealed by staining for α-actinin (green).
ET-1-stimulated myocytes also express ANF, which is manifest as a
perinuclear ring of immunoreactivity (red). ANF is a robust indicator of
hypertrophy [57]. DAPI (4′,6-diamidino-2-phenylindole)-stained nuclei
are indicated in blue. The white scale bar represents 20 µm.
models, support this concept [21,24]. Moreover, the acute
enhancement of Ca2+ cycling experienced by myocytes
during periods of increased workload or under stress is
induced by the same neurohumoral factors, such as adrenalin
and ET-1, that also induce hypertrophy when chronically
applied [15,25]. The direct role of Ca2+ for the induction of
hypertrophy is also suggested by evidence obtained using
transgenic models. For example, transgenic overexpression
of the archetypal cellular Ca2+ sensor, CaM (calmodulin),
induces hypertrophy [26]. It is clear that Ca2+-activated
CaM has major signalling targets involved in the stimulation
of hypertrophic gene transcription: the Ca2+/CaM-activated
serine/threonine phosphatase, calcineurin [also known as
PP2B (protein phosphatase 2B)] [23], CAMTA2 (CaM-
binding transcription activator 2) [27] and the delta isoform
of CaMKII (Ca2+/CaM-dependent protein kinase II) [23].
During the induction of hypertrophy, activated calcineurin
dephosphorylates NFAT3 (nuclear factor of activated T-cells
3), leading to its nuclear translocation and induction of target
genes bearing NFAT-binding sequences in their promoters.
The role of this linear pathway in cardiac myocytes was
elegantly delineated by a series of publications from the
Molkentin and Olsen laboratories, which showed that
hypertrophy could be induced by transgenic expression of
a mutated constitutively active calcineurin or of an activated
form of NFAT [28]. CaMKII signalling is linked to regu-
lation of hypertrophic gene transcription through inducing
the phosphorylation of HDACs (histone deacetylases) in the
nucleus, resulting in their nuclear export and removal of their
inhibitory effect on gene transcription [29]. This pathwaywas
unravelled using transgenic expression of CaMK inhibitor
peptides in the nucleus and non-phosphorylatable forms of
HDAC together with the use of knockout strategies [30,31].
Moreover, in response to prohypertrophic signals, HDACs
are observed to translocate out of the nucleus [32]. CAMTA2
Figure 2 Signalling to cardiac hypertrophy
The Figure shows the intracellular pathways that are activated down-
stream of diverse prohypertrophic factors. Many of these stimuli activate
increases in both Ca2+ cycling and other cellular signal-transduction
cascades such as those mediated by PKC, MAPK and PKB (protein
kinase B). Certain stimuli also induce increases in intracellular InsP3,
which subsequently promotes Ca2+ release through InsP3Rs that are
located under the plasmalemma adjacent to RyRs or around the nucleus.
Ca2+ release through the plasmalemmal InsP3Rs may contribute to
their inotropic function by sensitizing RyRs located there whereas Ca2+
release through nuclear InsP3Rs may play a role in regulating hypertro-
phic gene transcription. Whether these nuclear InsP3Rs release Ca2+
directly into the nucleus or into the adjacent cytosol is not clear.
Hypertrophic gene transcription is activated downstream of MAPK,
PKC and PKB signalling pathways (purple arrow). Gene transcription
is also induced by changes in Ca2+ in the cytosol (orange arrow) or
increases in Ca2+ in the nucleus (green arrow), where it is sensed
by appropriately localized Ca2+ sensors/transcriptional activators/
co-activators. Hypertrophic remodelling is associated with increased
cardiac muscle mass as well as an increase in Ca2+ signalling capacity
(black dashed arrow). During heart failure, Ca2+ signalling capacity may
be decreased (grey dashed arrow). VOCs, voltage-operated channels.
is themost recently describedCa2+-regulator of hypertrophic
gene transcription [27]. It elicits its effect by acting as a co-
activator of transcription factors involved in hypertrophic
gene transcription. In non-stimulated cells, it remains inactive
through interaction with HDACs [27]. HDACs are also
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sensitive to regulation by PKC, providing a further Ca2+ link
to DNA modification [33].
Encoding specificity in Ca2+ signals
Despite the many observations that suggest the sufficiency
of enhanced Ca2+ cycling for hypertrophic remodelling, it
is not clear how this signalling role of Ca2+ can be encoded
above the noise of the bulk changes in Ca2+ that occur in the
myocyte during every heart beat. Indeed, since these CaM-
regulated pathways detect changes in intracellular Ca2+ in
the submicromolar range, it would be predicted that they
would be activated by everyCa2+ transient during every heart
beat, and, moreover, their activity would be further increased
by inotropy. This ‘Ca2+ only’ model for the induction
of hypertrophy would, however, not be advantageous for
the myocyte; the array of phenotypic changes associated
with hypertrophy, which include re-expression of foetally
expressed genes such as ANF (atrial natriuretic factor;
Figure 1), would be induced at the functional and energetic
expense of the myocyte without benefit. How specificity
could be imposed upon the Ca2+ signal is therefore not clear.
At themost basic level, amechanismwould involve the simple
integration of either an increase in the frequency and/or
amplitude of the action potential-induced Ca2+ transient by
the transcription machinery [34]. This would be determined
by the equilibrium between the rate of activation and
inactivation of theCa2+ sensor aswell as the rates of activation
and inactivation of its target. For example, calcineurin res-
ponds to repetitive, low-amplitude Ca2+ transients, whereas
CaMKII is activated preferentially by Ca2+ spikes that are
transient and of high amplitude [35,36]. The equilibrium
could also be shifted in favour of the activated prohyper-
trophic state by an increase in the diastolic Ca2+ level. This
could occur through decreased Ca2+ clearance mechanisms
or enhanced activation of Ca2+-release channels on the SR
(sarcoplasmic reticulum). The induction of hypertrophy by
overexpression of canonical members of the TRP channels
(TRPCs) is also suggestive of a role of diastolic Ca2+ in
hypertrophic signalling [37].
A more attractive proposal is that the subcellular location
of the Ca2+ signal responsible for the induction of gene
transcription is different from that which stimulates con-
traction. Indeed, elegant work from the Bers laboratory has
shown that a Ca2+ signal generated in a microdomain around
the nucleus can promote the activation of a hypertrophy-
associated gene reporter construct [32]. Moreover, nuclear
localized InsP3R [Ins(1,4,5)P3 receptor]Ca2+ release channels
were shown to be involved in causing the depletion of
the nuclear Ca2+ store, which then promoted the nuclear
export of HDAC (Figure 2). This situation is analogous
to that observed in skeletal muscle, where Ca2+ is released
from nuclear localized InsP3Rs directly into the nucleoplasm,
resulting in phosphorylation of the CREB (cAMP-response-
element-binding protein) transcription factor [38]. Whether
Ca2+ is released into the nucleoplasm directly or reaches
there via release into the cytosol adjacent to the nucleus in
cardiac myocytes remains to be determined. A further point
of debate is whether this nuclear Ca2+ store is distinct from
the SR. Although fluorescence recovery after photobleaching
experiments indicate that it is contiguous with the SR [39],
the requirement of the ER (endoplasmic reticulum) Ca2+-
binding protein calreticulin for cardiac development suggests
that the ER has a specialized role in the cardiac myocyte [40].
The induction of hypertrophy as a result of enhancement
of store-operated Ca2+ entry by expression of TRPC family
members also supports a distinct signalling role for the ER in
the cardiac myocyte [37].
This idea that Ca2+ is sufficient for hypertrophic re-
modelling may, however, represent an over simplification
of signalling in the cardiac myocyte. The phospholamban-
knockout mouse, for example, exhibits a constitutive ino-
tropic state yet no hypertrophy, suggesting that other signals
are required for the induction of hypertrophic remodell-
ing [41]. Lessons gained over the past decade have indicated
that signalling pathways are interdependent and co-regulated
and are not generally simple linear pathways that link a
receptor to its target. This butterfly effect therefore needs
careful consideration. It is possible that evidence gained using
transgenic overexpression approaches, although valuable,
demonstrates only the possible functions of proteins in the
hypertrophic response. It is plausible that they have been
effective simplydue to the ability of the overexpressedprotein
concerned to overcome numerous regulatory checkpoints in
the cardiac myocyte signalling web. The presence of multiple
regulatory sequences in the promoters of genes involved in
the hypertrophic response suggests that this is the case.
Based on this concept, it is likely that hypertrophic
gene transcription acts as a coincidence detector of many
signalling inputs acting to continually assess both the cellular
environment and activity. The signalling outputs of ET
in the cardiac myocyte demonstrate this hypothesis. ET-1
is a vasoactive peptide that is found at elevated levels in
the circulation of heart failure patients. Moreover, it is a
potent prohypertrophic agonist. In cardiac muscle strips,
ET-1 also has chronotropic, inotropic and arrhythmogenic
effects. Myocytes express two receptors for ET-1, the ETAR
and theETBR [42]. TheETAR is aGq-coupled receptor,which
following activation stimulates phospholipase C to cleave
PtdIns(4,5)P2 into Ins(1,4,5)P3 and DAG (diacylglycerol)
[43]. InsP3 has recently been shown to have profound effects
on Ca2+ handling in the cardiac myocyte; it causes inotropy
and arrhythmogenic Ca2+ release events [25]. This effect
is a little surprising since InsP3Rs are expressed at a level
almost two orders of magnitude lower than RyRs (ryanodine
receptors),which are responsible for the largeCa2+ fluxes that
inducemyocyte contraction.Due to their special localizations
around the nucleus and under the plasmalemma, as well
as their ability to respond to stimuli other than Ca2+,
they may however be uniquely poised to enhance the
myocyte’s ability to respond and adapt to its environment
[25,32] (Figure 2). DAG also has important functions in the
myocyte. Its immediate target is PKC, which has possible
signalling functions in regulating Ca2+ homoeostasis as well
C©The Authors Journal compilation C©2007 Biochemical Society
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as ischaemia/reperfusion injury and inducing hypertrophy
[12,44]. This prohypertrophic effect of PKC has received
much attention and has been shownusing both transgenic and
pharmacological approaches to be in part via its activation of
the MAPK cascade [7,45].
Taken together, it is clear that signalling pathways that
converge to induce hypertrophy are complex and require
careful dissection. Due to the requirement for multiple inputs
for the induction of hypertrophy, it is likely that disruption
of any one of these pathways has a profound effect. Indeed,
numerous gain- and loss-of-function animal models for
signalling proteins have a profound effect on cardiac growth.
Impact of hypertrophy and heart failure on
Ca2+ cycling in the cardiac myocyte
Through tipping the finely poised balance in myocyte
signalling, subtle changes in Ca2+ cycling observed dur-
ing physiology/pathophysiology may induce hypertrophy.
However, hypertrophic growth, either compensated or
decompensated, impacts on Ca2+ homoeostasis and EC
(excitation–contraction) coupling. In addition to increases in
cell size, adaptive hypertrophy is characterized by increased
Ca2+-signalling capacity. In this way, cardiac output is
maximized. A recurrent theme in studies that describe the
role of Ca2+ cycling in hypertrophied myocytes is that
the amplitude of each depolarization-induced Ca2+ signal
is increased and its rate of recovery increased [15]. This
modification of the Ca2+ signal is brought about by changes
in the expression and/or activity of Ca2+ handling proteins,
resulting in increased SR store loading as a result of an increase
in its Ca2+-sequestration capacity, decreased Na+/Ca2+-
exchanger activity as well as an increase in the duration of
the action potential [14,15,46]. As the heart progresses to
failure, however, its Ca2+-signalling capacity is decreased,
with Ca2+ release from the SR being of a lower magnitude
and being less co-ordinated [47]. A significant contributor
to this phenotype is a change in the ratio of the SERCA
(sarcoplasmic/endoplasmic-reticulum Ca2+-ATPase) pump
to its negative regulator phospholamban, which changes in
favour of phospholamban, resulting in less pump activity and
lower SR Ca2+ storage [48]. The Ca2+ available for the pump
is also sometimes decreased as a result of increased activity
of the Na+/Ca2+-exchanger [49]. The SR is also depleted
as a result of an increased leak through the RyR, which is
brought about through the positive effect of phosphorylation
and possible interaction with the immunophillin ligand
FKBP12.6 (12.6 kDa FK506-binding protein) upon RyR
activity [47,50]. Whether these changes in Ca2+ homoeostasis
are a cause or consequence of disease, as well as whether
they play a continued signalling role in the maintenance
of the hypertrophic state, remains a matter of debate.
Depending on the model being studied, both scenarios may
be important. For example, recapitulation of certain Ca2+-
cycling defects by overexpression of mutated Ca2+-handling
proteins (such as calsequestrin), by themselves are sufficient
to induce hypertrophy [51,52]. Interestingly, certain forms
of heart failure can be rescued by enhancing Ca2+ signalling,
for example by phospholamban deletion [48]. Furthermore,
increases in Ca2+ transients are observed at early stages in
the progression to hypertrophy [15]. The possibility that
hypertrophy can itself cause changes inCa2+ signals is derived
from transgenic models in which hypertrophy is induced
by overexpression of proteins not directly involved in
Ca2+ homoeostasis. For example, myocytes isolated from
mice transgenically overexpressing calcineurin also have
altered Ca2+-handling characteristics. In these animals, Ca2+
sequestration into the SR is increased through an up-
regulation of SERCA expression and a decrease in phos-
pholamban, both characteristic of hypertrophied myocytes
[53]. Paradoxically, this enhanced Ca2+ signalling and
associated contractility persist in individual myocytes
isolated from failing hearts that actually exhibit decreased
contractile properties. This discrepancy between contractility
of individual myocytes and the intact heart is proposed to be
due to increased fibrosis and decreased connexin-mediated
connectivity between individual myocytes. These studies
indicate that calcineurin signalling contributes to a positive-
feedback loop that promotes the enhanced signalling capacity
required for greater cardiac output as well as myocyte
hypertrophy and further calcineurin activation.
These results suggest that it is likely that hypertrophy
induced by genetic factors progresses differently from that
induced by conditions of physiological stress (pressure
overload or hormones); the requirement for an initiating
Ca2+ signal is lost but the enhanced Ca2+ signals required
to improve function are maintained. This enhanced Ca2+
signalling, however, has a negative effect on cell viability
resulting in apoptosis. Myocytes lost through this process
are replaced with fibroblasts, resulting in fibrosis of the heart
and decreased contractility and conductivity as observed in
the constitutively active calcineurin-overexpressing mouse
[53]. In the case of hypertrophy induced by mechanical or
hormonal stimuli, unlike that induced by genetic factors,
an increase in Ca2+ cycling may initiate hypertrophic
remodelling but as it progresses to heart failure, Ca2+ cycling
is decreased [15,47]. The time point at which the state
of the Ca2+ signalosome is assessed after the induction of
hypertrophy is critical.
There is no doubt that Ca2+ homoeostasis is severely
affected in heart failure models. In addition to changes
in Ca2+-handling protein expression and their effects on
Ca2+ transients, the Ca2+ signal and its relationship with
contraction are significantly affected by ultrastructural
alterations observed during heart failure. At this failing stage,
the t-tubular network in ventricular myocytes atrophies,
resulting in a decrease in the efficiency of coupling between
the action potential and Ca2+ release [54]. It has been
proposed that as well as an increase in distance between L-
type VOCCs (voltage-operated Ca2+ channels) and RyRs,
which decreases the probability of successful CICR (Ca2+-
induced Ca2+ release), due to t-tubule loss, some RyRs are
orphaned and no longer have an L-type channel partner [55].
These findings have recently been extended to the adaptive
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hypertrophy model, where, although there are no orphaned
RyRs, the distance between the L-type channel and the RyR
is increased. Thus there is a lower probability of the small
amount of Ca2+ entering through the L-type channels
stimulating Ca2+ release through the RyR (decreased gain)
[56].
Conclusions
It is established that Ca2+ signals encode multiple levels
of information. The cardiac myocyte, in terms of how it
responds both acutely and in the long term to its environment,
is an ultimate model of how the amplitude, timing and
localization of a Ca2+ signal can be used to specifically
control cellular output and cell fate. Research to understand
the interplay between these different Ca2+ codes and other
cellular signalling pathways and how they synergize to
ultimately determine cell fate will remain a focus of future
investigations.
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